The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 1: 120 - 125

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.01.020

Medical Examination and Clinical Diagnosis

Evaluate value of serum PLOD3 and CYFRA21⁃1 on the efficacy of three⁃dimensional brachytherapy in patients with lung metastases

  • Tingting HU ,
  • Hongling LU ,
  • Xiaoming YIN ,
  • Qian LIU ,
  • Wei GUO ,
  • Yunchuan SUN
Expand
  • Department of Radiochemotherapy，Cangzhou Integrated Traditional Chinese and Western Medicine Hospital，Cangzhou 061000，Hebei，China

Received date: 2024-08-12

  Online published: 2025-01-14

Fold

Abstract

Objective To assess the prognostic value of serum lysine hydroxylase 3 （PLOD3） and cytokeratin 19 fragment （CYFRA21-1） in predicting the efficacy of three-dimensional brachytherapy in patients with pulmonary metastases. Methods A total of 102 patients with lung metastases who underwent three-dimensional brachytherapy at our hospital were selected as the lung metastasis group from August 2021 to August 2023. During the same period， a control group consisting of 60 healthy individuals who underwent physical examinations was selected. The lung metastasis group was further divided into an effective group （n = 66） and an ineffective group （n = 36） based on therapeutic outcomes. Enzyme-linked immunosorbent assay was employed to measure the levels of serum PLOD3 and CYFRA21-1. Multiple logistic regression analysis was conducted to identify factors influencing the efficacy of three-dimensional brachytherapy in the lung metastasis group. Receiver operating characteristic （ROC） curves were used to assess the predictive value of serum PLOD3 and CYFRA21-1 for treatment efficacy. Results The levels of serum PLOD3 and CYFRA21-1 in the case group were （34.47 ± 6.17） μg/L， （27.85 ± 5.14） μg/L， respectively， which exhibited significantly higher values compared to those observed in the control group （7.26 ± 2.21）μg/L，（9.31 ± 2.46）μg/L （P < 0.05）. A positive correlation was found between serum PLOD3 and CYFRA21-1 in the Lung metastasis group （r = 0.667， P = 0.000）. Logistic regression analysis revealed that multiple metastatic lesions along with elevated serum levels of PLOD3 and CYFRA21-1 were identified as risk factors for the efficacy of three-dimensional brachytherapy in patients with lung metastases （P < 0.05）. Furthermore， when combined with three-dimensional brachytherapy， the area under the curve （AUC） for serum PLOD3 and CYFRA21-1 was calculated as 0.868， demonstrating a superior performance compared to individual measurements of either serum PLOD3 alone （AUC = 0.815） or CYFRA21-1 alone （P < 0.05）. Conclusions The levels of serum PLOD3 and CYFRA21-1 are elevated in patients with lung metastases， exhibiting a significant correlation with the efficacy of three-dimensional brachytherapy. The combined utilization of these two biomarkers demonstrates a robust predictive value for treatment efficacy in patients suffering from lung metastases.

Key words： procollagen?lysine， 2?Oxoglutarate 5?Dioxygenase 3; cytokeratin 19 fragment antigen 21-1; pulmonary metastases; three-dimensional brachytherapy; treatment effectiveness

Cite this article

Tingting HU , Hongling LU , Xiaoming YIN , Qian LIU , Wei GUO , Yunchuan SUN . Evaluate value of serum PLOD3 and CYFRA21⁃1 on the efficacy of three⁃dimensional brachytherapy in patients with lung metastases[J]. The Journal of Practical Medicine, 2025 , 41(1) : 120 -125 . DOI: 10.3969/j.issn.1006-5725.2025.01.020

References

1 LIU Y， MAO D， WANG H， et al. Formation of pre-metastatic niches induced by tumor extracellular vesicles in lung metastasis［J］. Pharmacol Res， 2023，188（7）：1066-1079. doi:10.1016/j.phrs.2023.106669
2 JIAO Y， GUO X， WU H， et al. Surgery on Metastatic Foci is a Better Strategy for Stage Ⅳ Breast Cancer Patients with only Nonregional Lymph Node Metastasis［J］. Adv Ther， 2023，40（7）：3247-3262. doi:10.1007/s12325-023-02557-3
3 郑思捷，向佳，陈茜彤，等. 宽体能谱CT参数在鉴别诊断肺癌纵隔转移、非转移淋巴结与反应性增生淋巴结中的价值 ［J］. 实用医学杂志， 2024， 40 （14）： 2003-2008.
4 GUO X， HU W， GAO Z， et al. Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson's disease based on integrative analysis［J］. NPJ Parkinsons Dis， 2023，9（1）：82-94. doi:10.1038/s41531-023-00527-8
5 BAEK J H， YUN H S， KWON G T， et al. PLOD3 suppression exerts an anti-tumor effect on human lung cancer cells by modulating the PKC-delta signaling pathway［J］. Cell Death Dis， 2019，10（3）：156-167. doi:10.1038/s41419-019-1405-8
6 REN H， HU Y， XIE T， et al. Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer［J］. Oncol Lett， 2019，18（4）：4167-4175.
7 LIU C Z， ZENG H X， ZHAO J J， et al. The Validity of Using Human Squamous Cell Carcinoma Associated Antigen and Cytokeratin 19 Fragment Antigen 21-1 to Predict Postoperative Adjuvant Radiotherapy for Nonbulky Early-Stage Squamous Cell Carcinoma of the Cervix［J］. Int J Gynecol Cancer， 2017，27（5）：994-1000. doi:10.1097/igc.0000000000000990
8 EISENHAUER E A， THERASSE P， BOGAERTS J， et al. New response evaluation criteria in solid tumours： Revised RECIST guideline （version 1.1） ［J］. Eur J Cancer， 2009，45（2）：228-247. doi:10.1016/j.ejca.2008.10.026
9 NEZAMI N， KHORSHIDI F， MANSUR A， et al. Primary and Metastatic Lung Cancer： Rationale， Indications， and Outcomes of Thermal Ablation［J］. Clin Lung Cancer， 2023，24（5）：389-400. doi:10.1016/j.cllc.2023.03.012
10 胡婷婷， 鲁洪岭， 刘倩， 等. 肿瘤浸润淋巴细胞浸润程度对肺转移瘤患者三维近距离插植放疗疗效的影响［J］. 免疫学杂志， 2023，39（8）：714-721.
11 OLIVARES-URBANO M A， GRINAN-LISON C， MARCHAL J A， et al. CSC Radioresistance： A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer［J］. Cells， 2020，9（7）：1651-1666. doi:10.3390/cells9071651
12 LI W H， HUANG K， WEN F B， et al. PLOD3 regulates the expression of YAP1 to affect the progression of non-small cell lung cancer via the PKCdelta/CDK1/LIMD1 signaling pathway［J］. Lab Invest， 2022，102（4）：440-451. doi:10.1038/s41374-021-00674-7
13 BAEK J H， YUN H S， KWON G T， et al. PLOD3 promotes lung metastasis via regulation of STAT3［J］. Cell Death Dis， 2018，9（12）：1138-1149. doi:10.1038/s41419-018-1186-5
14 YUN H S， BAEK J H， YIM J H， et al. Radiotherapy diagnostic biomarkers in radioresistant human H460 lung cancer stem-like cells［J］. Cancer Biol Ther， 2016，17（2）：208-218. doi:10.1080/15384047.2016.1139232
15 FU L， WANG R， YIN L， et al. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer： A meta-analysis［J］. Int J Biol Markers， 2019，34（3）：251-261. doi:10.1177/1724600819868234
16 CHEN F， ZHANG X. Predictive value of serum SCCA and CYFRA21-1 levels on radiotherapy efficacy and prognosis in patients with non-small cell lung cancer［J］. Biotechnol Genet Eng Rev， 2023，13（5）：1-10.
17 MEI X， ZHU X， ZUO L， et al. Predictive significance of CYFRA21-1， squamous cell carcinoma antigen and carcinoembryonic antigen for lymph node metastasis in patients with esophageal squamous cancer［J］. Int J Biol Markers， 2019，34（2）：200-204. doi:10.1177/1724600819847999
18 ZHANG L， LIU D， LI L， et al. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients［J］. BMC Cancer， 2017，17（1）：96-107. doi:10.1186/s12885-017-3070-6
19 JAROSZ-BIEJ M， SMOLARCZYK R， CICHON T， et al. Tumor Microenvironment as A "Game Changer" in Cancer Radiotherapy［J］. Int J Mol Sci， 2019， 20（13）：3212-3227. doi:10.3390/ijms20133212
20 LI S， WEI W， FENG Z， et al. Role of Serum CYFRA 21-1 in Diagnosis and Prognostic in Colorectal Liver Metastases［J］. Cancer Manag Res， 2023，15（9）：601-614. doi:10.2147/cmar.s410477
21 JU M， GE X， DI X， et al. Diagnostic， Prognostic， and Recurrence Monitoring Value of Plasma CYFRA21-1 and NSE Levels in Patients with Esophageal Squamous Cell Carcinoma［J］. Front Oncol， 2022， 21（11）：7893-7899.
22 ZHANG R， TIAN W， ZHAO H， et al. Effect of neoadjuvant therapy on serum transforming growth factor-β， squamous cell carcinoma associated antigen， and prognosis in patients with locally advanced esophageal cancer［J］. Cell Mol Biol （Noisy-le-grand）， 2023， 69（5）：112-118. doi:10.14715/cmb/2023.69.5.18
Options
Outlines

/

〈 〉